Comparison of the effects of prophylactic antibiotic therapy and cost-effectiveness between cefazolin (CEZ) and Sulbactam/Ampicillin (SBT/ABPC) in gastric cancer surgery employing clinical pathway

Yakugaku Zasshi

Volumn 124, Issue 11, 2004, Pages 815-824

  Ise, Yuya ^a   Hagiwara, Ken ^a,b   Saitoh, Setsuo ^b   Honjo, Kazuyoshi ^a   Soh, Shizuka ^a   Kato, Ayumi ^a   Katayama, Shirou ^a   Nishizawa, Kenji ^a   Hirano, Masaaki ^a   Yoshiyuki, Toshiro ^a   Kiyama, Teruo ^a   Mitsuhashi, Kyoko ^a   Kamei, Miwako ^c   Shiragami, Makoto ^c  

^a NIPPON MEDICAL SCHOOL HOSPITAL   (Japan)

^b JOSAI UNIVERSITY   (Japan)

^c NIHON UNIVERSITY   (Japan)

Author keywords

Cefazolin (CEZ); Clinical pathway; Cost effective analysis; Gastric cancer; Prophylactic antibiotic therapy; Sulbactam Ampicillin (SBT ABPC)

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; CEFAZOLIN; SULTAMICILLIN; AMPICILLIN; SULBACTAM;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARTICLE; BODY TEMPERATURE DISORDER; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DRUG EFFECT; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NURSE; NURSING; OPERATION DURATION; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE INFECTION; POSTOPERATIVE PERIOD; SEX RATIO; STOMACH CANCER; SURGICAL TECHNIQUE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; BACTERIAL INFECTION; CLINICAL PATHWAY; COST BENEFIT ANALYSIS; ECONOMICS; GASTRECTOMY; MICROBIOLOGY; MIDDLE AGED; POSTOPERATIVE COMPLICATION; RETROSPECTIVE STUDY; STOMACH TUMOR;

AGED; AMPICILLIN; ANTIBIOTIC PROPHYLAXIS; CEFAZOLIN; COST-BENEFIT ANALYSIS; CRITICAL PATHWAYS; FEMALE; GASTRECTOMY; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SULBACTAM;

EID: 16644402472     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.124.815     Document Type: Article

References (13)

1. Nakanishi K., Ogawa R., Takayanagi K., Tokunaga A., Hasegawa S., J. Nippon Med. Sch., 67, 468-472 (2000).
2. Ise Y., Honjo K., Soh S., Senoo M., Katayama S., Nishizawa K., Hirano M., Mitsuhashi K., Yoshiyuki T., Kiyama T., Jpn. J. Pharm. Health Care Sci., 29, 28-32 (2003).
3. Ise Y., Honjo K., Soh S., Senoo M., Katayama S., Hirano M., Mitsuhashi K., Yoshiyuki T., Kiyama T., J. Nippon Med. Sch., 70, 53-56 (2003).
4. Kiyama T., Tajiri T., Yoshiyuki T., Mitsuhashi K., Ise Y., Mizutani T., Okuda T., Fujita I., Masuda K., Katoh S., Matsukura N., Tokunaga A., Hasegawa S., J. Nippon Med. Sch., 70, 263-269 (2003).
5. Ise Y., Honjo K., Soh S., Senoo M., Katayama S., Hirano M., Mitsuhashi K., Yoshiyuki T., Kiyama T., J. Jpn. Hosp. Pharm., 39, 205 -207 (2003).
6. Yoshiyuki T., Onda M., Tokunaga A., Onodera H., Mizutani T., Kiyama T., Hasegawa H., Kato S., Matsukura N., Prog. Med., 21, 1372-1373 (2003).
7. Japanese Society and Chemotherapy, Jpn. Soc. Chemother., 45, 553-641 (1997).
8. Deguchi K., Suzuki Y., Ishihara R., Ishii Y., Nakazawa A., Jpn. Soc. Chemother., 45, 955-964 (1997).
9. Tateda E., Asada K., Hiramatsu K., Modern Media, 42, 113-123 (1996).
10. Satoh T., Iwai S., Tanaka T., Med. Postgrad., 30, 589-594 (1992).
11. Yoshida I., Sugimori G., Higashiyama I., Kimura Y., Yamano Y., Jpn. Soc. Chemother., 51, 209-232 (2003).
12. Sumiyama Y., Kusachi S., J. Jpn. Med. Assoc., 124, 1612-1613 (2000).
13. Ise Y., Honjo K., Katayama S., Hirano M., Furukawa K., Jpn. J. Pharm. Health Care Sci., 28, 47-50 (2002).